GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Cash Flow for Dividends

Gan & Lee Pharmaceuticals Co (SHSE:603087) Cash Flow for Dividends : ¥0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co Cash Flow for Dividends?

Gan & Lee Pharmaceuticals Co's cash flow for dividends for the three months ended in Sep. 2024 was ¥0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2024 was ¥0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Gan & Lee Pharmaceuticals Co's annual payment of dividends declined from Dec. 2021 (¥-225 Mil) to Dec. 2022 (¥-168 Mil) and declined from Dec. 2022 (¥-168 Mil) to Dec. 2023 (¥0 Mil).

Gan & Lee Pharmaceuticals Co Cash Flow for Dividends Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co Cash Flow for Dividends Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -200.55 -224.62 -168.46 -

Gan & Lee Pharmaceuticals Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gan & Lee Pharmaceuticals Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan & Lee Pharmaceuticals Co Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Gan & Lee Pharmaceuticals Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Cash Flow for Dividends
Comparable Companies
SZSE:300888 SZSE:002432 SZSE:002294 SHSE:688050 SHSE:688301 SZSE:300677 SZSE:300595 SZSE:300573 SHSE:688289 SHSE:688029 ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Website
http://www.ganlee.com
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines